Jazz Entered into an Exclusive License Agreement with Zymeworks to Develop and Commercialize Zanidatamab for Cancers
- Zymeworks will receive a $50M up front, a second one-time fee of $325M & is also eligible to receive ~$525M upon achievement of regulatory milestones, ~$862.5M in commercial milestones with a total deal value of ~$1.76B along with royalties b/w 10% and 20% on Jazz's net sales
- Jazz to get an exclusive license to develop & commercialize zanidatamab across all indications in the US, EU, Japan & all other territories (excl. Asia/Pacific territories previously licensed by Zymeworks)
- The (HERIZON-BTC-01) trial results for zanidatamab in BTC are expected at the end of 2022. Zanidatamab is a HER2-targeted bispecific Ab with biparatopic binding which showed compelling anti-tumor activity in multiple HER2-expressing cancers as monothx. & in combination with CT & other agents
Ref: Jazz | Image: Jazz
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected].